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Abstract
Background: Pneumococcal polysaccharide vaccine (PPV) is recommended for all adults 65 years
of age and older and for younger adults with high-risk conditions. While data from national surveys
provide information on the proportion of adults 65 years of age and older reporting ever receipt
of PPV they do not collect more detailed information, such as age at vaccination or the total
number of vaccinations received. In addition, there is relatively little information available on PPV
coverage in younger adults with chronic conditions. To assess contemporary patterns of
pneumococcal vaccination and revaccination of adults, we conducted a cross-sectional study of
adults enrolled in medical care organizations (MCOs) participating in the Vaccine Safety Datalink
project.
Methods: The study population included 1.5 million adults 25 years of age and older enrolled in
the four participating MCOs on December 1, 2006. PPVs administered to members of the study
population prior to that date were identified from computerized immunization registries
maintained by the MCOs.
Results: Among the general population of adults 25 through 64 years of age, vaccine coverage
increased from 2% in the 25–29 year old age-group to 26% in the 60–64 year old age-group. In all
age-groups, coverage was substantially higher in persons defined as having a chronic high risk
condition. This was particularly true for diabetes mellitus, with vaccine coverage of over 50% in the
lower age-groups and 75% in those 60–64 years of age. Among adults 65 years of age and older,
82% had received at least one PPV and 18% had received two or more PPVs.
Conclusion: We found higher levels of PPV coverage among adults 65 years of age and older and
among younger adults with diabetes mellitus than reported by national surveys and for those
groups PPV coverage approached the Healthy People 2010 national objectives. These results suggest
that achieving those objectives for PPV is possible and that high vaccination coverage may be
facilitated by vaccine tracking and reminder systems.
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Background
In the United States, pneumococcal polysaccharide vac-
cine (PPV) is recommended for all adults 65 years of age
and older and for younger adults with certain chronic con-
ditions, such as diabetes mellitus [1]. Seniors who
received one or more doses of PPV when younger than 65
should receive another dose on or after their 65th birthday
(and at least five years after the prior vaccination). Once
vaccinated after the age of 65, however, no additional
doses of PPV are recommended, and revaccination is not
recommended for immunocompetent persons under age
65. National surveys such as the Behavioral Risk Factor
Surveillance System (BRFSS) survey indicate that pneu-
mococcal vaccine coverage in adults ≥65 years has greatly
increased over the past two decades, with 66% of adults
≥65 years interviewed in the 2005 BRFSS survey reporting
past receipt of PPV [2].
While data from the BRFSS and similar surveys provide
information on the proportion of seniors reporting ever
receipt of PPV they do not collect more detailed informa-
tion, such as age at vaccination or the total number of vac-
cinations received. In addition, there is relatively little
information available on PPV coverage in younger adults
with chronic conditions.
Additional information on current patterns of PPV use in
adults ≥65 years and younger adults would be helpful in
decision making regarding current and future strategies
for prevention of pneumococcal infection. For example,
knowledge of the proportion of adults ≥65 years who
received PPV before age 65 would aid in decisions regard-
ing possible strategies for use of newer pneumococcal vac-
cines, for which the immunologic response may differ in
PPV naïve and previously vaccinated persons. To assess
contemporary patterns of pneumococcal vaccination and
revaccination of adults, we conducted a cross-sectional
study of approximately 1.5 million adults enrolled in
medical care organizations (MCOs) participating in the
Vaccine Safety Datalink project.
Methods
The Vaccine Safety Datalink project was established in
1991 to monitor and evaluate vaccine safety and includes
eight participating MCOs with a combined patient popu-
lation of over 8.8 million members. Project staff at each
MCO prepare annual data files that contain demographic
and medical information derived from MCO administra-
tive data systems. These data files include information on
age, sex, health plan enrollment, vaccination, and ambu-
latory and inpatient medical encounters. The specific
goals, structure, and data characteristics of the Vaccine
Safety Datalink have been described previously [3,4].
The study population for this assessment included adults
25 years of age and older who were enrolled in a partici-
pating MCO on December 1, 2006 and who had been
continuously enrolled for at least five years prior to that
date. Participating MCOs included Northern California
Kaiser Permanente, Northwest Kaiser Permanente (Ore-
gon), Group Health Cooperative (Washington), and
Marshfield Clinic (Wisconsin). These MCOs were selected
for this study from among the eight MCOs in the Vaccine
Safety Datalink because of the availability of historical
data on adult vaccinations.
Pneumococcal polysaccharide vaccinations administered
to members of the study population prior to December 1,
2006 were identified from computerized immunization
registries maintained by the MCOs. For persons with
more than one PPV recorded, the earliest vaccination
recorded was defined as the first vaccination and subse-
quent vaccinations were defined as separate vaccinations
if there was an interval of at least 91 days since the prior
vaccination. If the interval between two consecutive
recorded vaccinations was 90 days or less the more recent
vaccination was defined as a duplicate and was not
counted as a separate vaccination. This interval was
selected because repeated pneumococcal vaccinations
should not be administered within a 90 day interval and
data entry errors can occur. Multiple entries within this
window were rare and a second PPV with an administra-
tion date less than 91 days following a prior PPV
accounted for only 1949 of the 563,524 (0.3%) PPVs
identified.
The presence or absence of chronic conditions was
defined by International Classification of Diseases 9th Revi-
sion Clinical Modification (ICD9-CM) codes assigned to
inpatient or outpatient medical encounters during 2006.
Diabetes mellitus was defined by ICD9-CM code 250,
congestive heart failure (CHF) by codes 402.01, 402.11,
402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93,
425, and 428, and chronic obstructive pulmonary disease
(COPD) by codes 491.1 through 492.8, 494, and 496.
These conditions were selected for evaluation of vaccina-
tion patterns because they are generally not transient and
expected to be reasonably common in adults under 65
years of age. In addition, a category of no disease was
defined by the absence of the codes listed above as well as
codes for ischemic cardiac disease (410 through 414),
asthma (493), emphysema (510), cancer (140–155, 157–
171, 173–208), renal disease (580–588, 591, V56), rheu-
matologic disease (710, 714), and organ transplantation
(996).
The study was approved by the Institutional Review
Boards of the participating MCOs.BMC Infectious Diseases 2009, 9:37 http://www.biomedcentral.com/1471-2334/9/37
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Results
The study population included 1,527,357 adults 25 years
of age and older. Of those, 421,677 (28%) were 65 years
of age and older and 831,869 (54%) were female. The
proportion of adults with at least one PPV recorded prior
to December 1, 2006, by year of age, is shown in Figure 1.
Adults 25 through 64 years of age
Among the general population of adults 25 through 64
years of age, vaccine coverage increased from 2% in the
25–29 year old age-group to 26% in the 60–64 year old
age-group (Table 1). In all age-groups, coverage was sub-
stantially higher in persons defined as having a chronic
high risk condition. This was particularly true for diabetes
mellitus, with vaccine coverage of over 50% in the lower
age-groups and 75% in those 60–64 years of age.
Revaccination was generally uncommon in adults 25
through 64 years of age, although there were trends for a
higher prevalence of revaccination in persons with
chronic disease and in the older age-groups. The highest
prevalence of revaccination, 17%, was in persons 60–64
years of age with CHF.
Adults 65 years of age and older
Eighty-two percent of adults 65 years of age and older had
ever received PPV and 73% had received at least one PPV
on or after age 65 (Table 2). There were no differences in
patterns of receipt of PPV by sex; vaccine coverage was
82% in females and 81% in males. Vaccine coverage for
each of the four MCOs was 74%, 81%, 86%, and 87%;
differences in coverage were not due to differences in age
distribution of the populations in the MCOs. Overall,
lower coverage (67%) was seen in the 65–69 year old age-
group than in the older age-groups and coverage among
those 70 and older was 87%. Persons with chronic illness
tended to have higher vaccination coverage.
Eighteen percent of adults ≥65 years had two or more
PPVs recorded and 7% had received at least two PPVs on
or after age 65. Nearly all who received more than one
PPV had a total of two vaccinations recorded; only 0.6%
had three or more PPVs recorded. Among those who
received two PPVs on or after age 65, the interval between
the vaccinations was less than five years for 25%, was
from five through seven years in 43%, and was eight years
or more for the remaining 32%.
Proportion of adults 25–89 years of age with ever receipt of PPV, by year of age and chronic condition Figure 1
Proportion of adults 25–89 years of age with ever receipt of PPV, by year of age and chronic condition. Values 
are shown only for year of age categories with a denominator of at least 100 persons. The age groups shown include 28–89 
years for diabetes mellitus, 46–89 years for CHF, 44–89 years for COPD, and 25–89 for all. CHF, congestive heart failure. 
COPD, chronic obstructive pulmonary disease.
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Table 1: Patterns of PPV vaccination and revaccination in adults 25 through 64 years of age with and without chronic conditions.
All Diabetes 
mellitus
Congestive 
heart failure
Chronic 
obstructive 
pulmonary 
disease
No 
disease*
N ≥1 PPV ≥2 PPV N ≥1 PPV ≥2 PPV N ≥1 PPV ≥2 PPV N ≥1 PPV ≥2 PPV N ≥1 PPV ≥2 PPV
Age
25–29 49,454 2% <1% 537 55% 2% 38 26% 8% 49 58% 8% 45,844 1% <1%
30–34 80,524 2% <1% 1315 51% 2% 89 46% 1% 77 29% 1% 74,078 1% <1%
35–39 116,619 4% <1% 3122 53% 3% 211 46% 6% 193 21% 3% 105,657 2% <1%
40–44 146,108 6% <1% 6053 57% 3% 339 47% 6% 484 29% 3% 129,053 3% <1%
45–49 175,591 8% <1% 10,857 62% 4% 782 53% 9% 1050 35% 5% 149,335 4% <1%
50–54 190,569 12% 1% 16,934 65% 5% 1442 61% 10% 1997 40% 6% 153,632 5% <1%
55–59 192,859 18% 1% 23,591 69% 7% 2567 66% 11% 3445 49% 7% 144,352 8% <1%
60–64 153,956 26% 3% 23,737 75% 9% 3386 74% 17% 5006 58% 11% 104,388 13% 1%
Total 1,105,680 12% 1% 86,146 67% 6% 8854 65% 13% 12,301 58% 8% 906,339 5% <1%
*See methods for the definition of persons with no disease.BMC Infectious Diseases 2009, 9:37 http://www.biomedcentral.com/1471-2334/9/37
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The patterns of age at the time of first pneumococcal vac-
cination among adults ≥65 years demonstrate changes in
PPV availability and use over time (Table 3). Adults in
their 80s tended to have received their first PPV in their
70s or later, while younger persons had a greater likeli-
hood of having received PPV before age 65 or soon after
age 65.
Discussion and Conclusion
In this assessment of 1.5 million adults enrolled in four
MCOs we found much higher levels of PPV coverage than
has been reported in national surveys of the United States
population. For example, 82% of adults ≥65 years in our
study population had received at least one PPV, compared
with a median state specific coverage rate among adults
≥65 years of 66% in the 2005 BRFSS survey and 57% in
the 2006 National Health Interview Survey (NHIS) [2].
We also found much higher rates of coverage among
adults less than 65 years of age with diabetes mellitus than
has been reported by those national surveys. In our study
population, over half of adults less than 65 years of age
with diabetes had received PPV, even in the youngest age
groups, compared to the lower estimates of coverage in
these age groups reported by the 2005 BRFSS survey
(Table 4).
Possible reasons for the higher vaccination coverage that
we observed include our assessment of vaccination status
based on data from computerized immunization regis-
tries, which may be a more sensitive indicator of past vac-
cination than self-report [3]. In addition, our MCO study
population included, by definition, only insured persons,
a group that is likely have better access to preventive care
services than uninsured persons. Further, the MCOs
included in this study were selected on the basis of avail-
ability of historical adult vaccination data, which may
also indicate a greater focus on immunization services in
those organizations. During the study period some of the
participating MCOs had systems to prompt providers to
administer PPV to an eligible adult which likely facilitated
vaccine delivery. Lastly, we defined diabetes mellitus and
other chronic conditions by diagnostic codes assigned to
medical encounters, and so all persons defined as having
a chronic condition in our analyses had at least one med-
Table 2: Patterns of PPV vaccination and revaccination in adults ≥65 years.
N ≥1 PPV at any age ≥1 PPV prior to age 65 ≥1 PPV on or after age 65 ≥2 PPV ever ≥2 PPV on or after age 65
Age %
65–69 111,019 67 34 44 15 <1
70–74 105,789 86 28 78 23 3
75–79 87,328 88 10 87 18 11
80–84 65,758 88 1 88 14 14
85–89 36,033 86 <1 86 14 14
90+ 15,750 83 0 83 13 13
≥65 421,677 82 18 73 18 7
≥65 with diabetes 86,258 91 31 77 27 8
≥65 with CHF 35,328 90 17 83 24 12
≥65 with COPD 36,623 90 23 82 27 12
CHF, congestive heart failure. COPD, chronic obstructive pulmonary disease.
Table 3: Age at receipt of first recorded PPV, for adults ≥65 years with at least one prior PPV recorded.
Age as of December 1, 2006
65–69 70–74 75–79 80–84 85–89 90+
Age at first recorded PPV N (%)
40–44 3 (<1) 0 0 0 0 0
45–49 60 (<1) 6 (<1) 0 0 0 0
50–54 1824 (2) 114 (<1) 28 (<1) 0 0 0
55–59 12,612 (17) 3296 (4) 216 (<1) 26 (<1) 0 0
60–64 23,698 (32) 25,990 (29) 8129 (10) 492 (<1) 56 (<1) 0
65–69 35,957 (48) 53,893 (59) 38,933 (50) 10,613 (18) 696 (2) 34 (<1)
70–74 - 7321 (8) 24,717 (32) 24,530 (42) 6194 (20) 330 (2)
75–79 - - 5194 (7) 18,382 (32) 12,652 (41) 2278 (17)
80–84 - - - 3761 (6) 9563 (31) 4790 (37)
85–89 - - - - 1859 (6) 4034 (31)
9 0 + -- --- 1 5 7 7  ( 1 2 )
Total 74,154 90,620 77,217 57,804 31,020 13,043BMC Infectious Diseases 2009, 9:37 http://www.biomedcentral.com/1471-2334/9/37
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ical encounter in the prior year, and this may select for
subgroups with higher vaccination coverage.
Data on race and ethnicity is generally not available in the
MCO data systems and so we could not evaluate differ-
ences in vaccination coverage by those factors. Data from
national surveys indicates that PPV coverage varies by race
and ethnicity and is higher in white, non-hispanics than
in either Hispanics or blacks (Table 4). If white persons
were relatively overrepresented in our MCO populations
then this could account in part for the variations in vac-
cine coverage estimates between our estimates and
national estimates. The prevalence of pneumococcal vac-
cination in our population remained higher than national
estimates for the white non-hispanic subgroup, however,
suggesting that vaccination coverage was higher in the
study population even after accounting for possible
demographic differences.
Despite the lack of a recommendation for administration
of a second PPV after age 65, receipt of two or more PPVs
after age 65 was not uncommon. This may be due in part
to a lack of understanding of the recommendations by
some care providers. It is possible that the proportion of
adults ≥65 years who have received two or more PPVs will
further increase as the prevalence of first vaccination in
adults rises over time. Among adults 50–64 years of age
with diabetes, CHF, or COPD, between 5 and 17% had
received two PPVs, depending on the condition and age
group.
The Healthy People 2010 objectives for pneumococcal vac-
cination in adults are to achieve 90% coverage of both
institutionalized and non-institutionalized persons 65
years of age and older and to achieve 60% coverage of
noninstitutionalized high-risk adults 18 through 64 years
of age http://www.healthypeople.gov/document/html/
objectives/14-29.htm. As of 2006, PPV coverage in our
study population approached the target for persons 65
years of age and older and for younger adults with diabe-
tes or CHF. While there are differences between our study
population of MCO members and the general U.S. popu-
lation, these results suggest that achieving the Healthy Peo-
ple 2010 national objectives for pneumococcal vaccine is
possible. Higher coverage may be facilitated by vaccine
tracking and reminder systems.
Table 4: Estimates of pneumococcal polysaccharide vaccine coverage in the United States from the 2005 Behavioral Risk Factor 
Surveillance System survey.
Group Age
(years)
% ever had pneumonia shot
All Diabetes*
All 25–29 10 29
30–34 9 17
35–39 10 27
40–44 10 30
45–49 11 30
50–54 14 34
55–59 21 41
60–64 30 48
65+ 64 69
White, Non-Hispanic 18–64 14 40
65+ 67 75
Black, Non-Hispanic 18–64 16 33
65+ 50 55
Hispanic 18–64 13 23
65+ 42 47
Has health care coverage 18–64 14 38
65+ 64 70
Does not have health care coverage 18–64 13 27
65+ 42 52
Data from the WEAT: Web Enabled Analysis Tool available at http://apps.nccd.cdc.gov/s_broker/htmsql.exe/weat/Freq_analysis.hsql.
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